ORBIMED ADVISORS LLC 13D and 13G filings for Theseus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-12-27 4:43 pm Unchanged | 2023-12-22 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,713,600 40.100% | 0 (Unchanged) | Filing |
| 2023-11-24 4:28 pm Unchanged | 2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,713,600 40.100% | 0 (Unchanged) | Filing |
| 2023-07-19 4:12 pm Purchase | 2023-07-17 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,713,600 40.700% | 479,932 (+2.78%) | Filing |
| 2023-03-14 4:19 pm Purchase | 2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,233,668 39.600% | 395,000 (+2.35%) | Filing |
| 2021-11-18 5:10 pm Unchanged | 2021-11-15 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 16,838,668 43.500% | 0 (Unchanged) | Filing |
| 2021-10-19 5:23 pm Purchase | 2021-10-12 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 16,838,668 44.900% | 16,838,668 (New Position) | Filing |